Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GS-248 for Raynaud's Phenomenon in Systemic Sclerosis
NCT04744207Phase 2Completed
- Sponsor
- Gesynta Pharma
- Start
- Dec 2020
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of vipoglanstat in Raynaud phenomenon, sponsored by Gesynta Pharma. Started Dec 2020; status: completed.
02
Drugs
vipoglanstat
03
Conditions
Raynaud phenomenon
Beyond the preview
Go deeper on NCT04744207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04744207.